These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013 [TBL] [Abstract][Full Text] [Related]
10. Complement and monocytes are essential for provoking glomerular injury in passive Heymann nephritis in rats. Terminal complement components are not the sole mediators of proteinuria. Hara M; Batsford SR; Mihatsch MJ; Bitter-Suermann D; Vogt A Lab Invest; 1991 Aug; 65(2):168-79. PubMed ID: 1881120 [TBL] [Abstract][Full Text] [Related]
11. A new role for complement in experimental membranous nephropathy in rats. Salant DJ; Belok S; Madaio MP; Couser WG J Clin Invest; 1980 Dec; 66(6):1339-50. PubMed ID: 7440718 [TBL] [Abstract][Full Text] [Related]
12. Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Zoja C; Benigni A; Camozzi D; Corna D; Longaretti L; Todeschini M; Remuzzi G Kidney Int; 2003 Sep; 64(3):857-63. PubMed ID: 12911535 [TBL] [Abstract][Full Text] [Related]
13. Studies on antinephritic effect of TJ-8014, a new Japanese herbal medicine (4): Effects on accelerated passive Heymann nephritis in rats. Hattori T; Ito M; Suzuki Y Jpn J Pharmacol; 1990 Nov; 54(3):265-75. PubMed ID: 1708836 [TBL] [Abstract][Full Text] [Related]
14. Receptor antagonists of platelet-activating factor do not influence the development of passive Heymann nephritis. Salvidio G; Brentjens J; Camussi G J Lipid Mediat; 1991; 3(2):197-204. PubMed ID: 1665716 [TBL] [Abstract][Full Text] [Related]
15. Glomerular charge barrier and development of proteinuria in passive Heymann nephritis. Christiansen RE; Kolmannskog O; Leh S; Iversen BM; Tenstad O Kidney Blood Press Res; 2008; 31(3):203-9. PubMed ID: 18544954 [TBL] [Abstract][Full Text] [Related]
16. Ultrastructural background of albuminuria in rats with passive Heymann nephritis. Arai T; Morimoto K; Masaoka H; Kaneko O; Mera J; Kojima K; Nagase M; Kobayashi S; Ohtake T; Hishida A Nephrol Dial Transplant; 1997 Dec; 12(12):2542-8. PubMed ID: 9430849 [TBL] [Abstract][Full Text] [Related]
17. Differential capacity of anti-RAP and anti-megalin antibodies to produce progressive passive Heymann nephritis - implications for the pathogenesis of idiopathic human membranous glomerulonephritis. Makker SP; Tramontano A J Pathol; 2006 Nov; 210(3):282-7. PubMed ID: 16981232 [TBL] [Abstract][Full Text] [Related]
18. Different effect of cyclosporine A and mycophenolate mofetil on passive Heymann nephritis in the rat. Blume C; Heise G; Hess A; Waldner C; Grabensee B; Schroer K; Heering P Nephron Exp Nephrol; 2005; 100(2):e104-12. PubMed ID: 15855806 [TBL] [Abstract][Full Text] [Related]
19. The long-term evolution of immune deposits in passive Heymann nephritis. Soares VA; Almeida DB Braz J Med Biol Res; 1992; 25(2):149-59. PubMed ID: 1339511 [TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of colchicine in experimental nephrotoxic serum nephritis in the rat. Penchas S; Charuzi I; Boss JH Eur J Clin Invest; 1979 Apr; 9(2 Pt 1):161-6. PubMed ID: 111949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]